Literature DB >> 34145316

Long-term clinical course and outcome in patients with primary Sjögren syndrome-associated interstitial lung disease.

Yun Jae Kim1, Jooae Choe2, Ho Jeong Kim3, Jin Woo Song4.   

Abstract

Interstitial lung disease (ILD) is the most common lung manifestation in patients with Sjögren syndrome (SJS) and is associated with poor outcomes. This study aimed to investigate the long-term clinical course and prognostic factors in patients with SJS-ILD. Clinical data and high-resolution computed tomography (HRCT) images of 62 patients with primary SJS-ILD were retrospectively analyzed (biopsy-proven cases, n = 16). The mean patient age was 59.8 years; 83.9% of the patients were females, and 38.7% showed a usual interstitial pneumonia (UIP) pattern on HRCT. The median follow-up period was 61.5 months. During follow-up, 15 patients (24.2%) died, 7 (11.3%) experienced acute exacerbation (AE), and 27 (43.5%) progressed. The 1-, 3- and 5-year survival rates were 93.5%, 85.8%, and 81.1%, respectively. Age (hazard ratio [HR]: 1.158, P = 0.003), C-reactive protein (CRP) level (HR: 1.212, P = 0.045), FVC (HR: 0.902, P = 0.005), and a UIP pattern on HRCT (HR: 4.580, P = 0.029) were significant prognostic factors in multivariable Cox analysis. In conclusion, death, AE, and ILD progression occurred in 25%, 10%, and 50% of the patients with SJS-ILD, respectively. Older age, higher CRP level, lower FVC, and a UIP pattern on HRCT indicated poor prognosis.

Entities:  

Year:  2021        PMID: 34145316     DOI: 10.1038/s41598-021-92024-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  28 in total

1.  A new model for classification of disease manifestations in primary Sjögren's syndrome: evaluation in a retrospective long-term study.

Authors:  K Asmussen; V Andersen; G Bendixen; M Schiødt; P Oxholm
Journal:  J Intern Med       Date:  1996-06       Impact factor: 8.989

2.  Interstitial lung disease in primary Sjögren's syndrome.

Authors:  F Roca; S Dominique; J Schmidt; A Smail; P Duhaut; H Lévesque; I Marie
Journal:  Autoimmun Rev       Date:  2016-09-25       Impact factor: 9.754

Review 3.  Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Authors:  David A Lynch; Nicola Sverzellati; William D Travis; Kevin K Brown; Thomas V Colby; Jeffrey R Galvin; Jonathan G Goldin; David M Hansell; Yoshikazu Inoue; Takeshi Johkoh; Andrew G Nicholson; Shandra L Knight; Suhail Raoof; Luca Richeldi; Christopher J Ryerson; Jay H Ryu; Athol U Wells
Journal:  Lancet Respir Med       Date:  2017-11-15       Impact factor: 30.700

4.  Clinical follow up study of 87 patients with sicca symptoms (dryness of eyes or mouth, or both).

Authors:  M Pertovaara; M Korpela; H Uusitalo; J Pukander; A Miettinen; H Helin; A Pasternack
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

Review 5.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

Review 6.  Pulmonary involvement in Sjögren syndrome.

Authors:  Maria Kokosi; Ellen C Riemer; Kristin B Highland
Journal:  Clin Chest Med       Date:  2010-09       Impact factor: 2.878

7.  Interstitial lung disease in primary Sjögren syndrome.

Authors:  Joseph G Parambil; Jeffrey L Myers; Rebecca M Lindell; Eric L Matteson; Jay H Ryu
Journal:  Chest       Date:  2006-11       Impact factor: 9.410

Review 8.  Skin involvement in systemic autoimmune diseases.

Authors:  Shadi Rashtak; Mark R Pittelkow
Journal:  Curr Dir Autoimmun       Date:  2008

Review 9.  Renal involvement in primary Sjögren syndrome.

Authors:  Hélène François; Xavier Mariette
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

10.  Is the heart affected in primary Sjögren's syndrome? An echocardiographic study.

Authors:  V A Vassiliou; I Moyssakis; K A Boki; H M Moutsopoulos
Journal:  Clin Exp Rheumatol       Date:  2008 Jan-Feb       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.